TWD 78.4
(-1.51%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 125.26 Million TWD | -8.86% |
2022 | 137.44 Million TWD | 151.79% |
2021 | 54.58 Million TWD | 41.25% |
2020 | 38.64 Million TWD | 1149.06% |
2019 | 3.09 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 16.78 Million TWD | -63.89% |
2024 Q2 | 16.78 Million TWD | 0.0% |
2023 Q2 | 16.14 Million TWD | 0.0% |
2023 Q4 | 46.49 Million TWD | 0.0% |
2023 Q1 | 16.14 Million TWD | -9.36% |
2023 FY | 125.26 Million TWD | -8.86% |
2023 Q3 | 46.49 Million TWD | 188.03% |
2022 Q3 | 17.8 Million TWD | 0.0% |
2022 FY | 137.44 Million TWD | 151.79% |
2022 Q4 | 17.8 Million TWD | 0.0% |
2021 FY | 54.58 Million TWD | 41.25% |
2020 FY | 38.64 Million TWD | 1149.06% |
2019 FY | 3.09 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
BIONET Corp. | 1.12 Billion TWD | 88.888% |
DIVA Laboratories, Ltd. | 893.84 Million TWD | 85.985% |
Genetics Generation Advancement Corp. | 592.5 Million TWD | 78.858% |
Welgene Biotech Co.,Ltd. | 280.54 Million TWD | 55.349% |
TFBS Bioscience Inc. | 231.91 Million TWD | 45.986% |